Portland, ORNCT06067438Now EnrollingIRB Ready

Atrial Fibrillation Clinical Trial in Portland, OR

Access cutting-edge atrial fibrillation treatment through this clinical trial at a research site in Portland. Study-provided care at no cost to qualified participants.

Sponsored by OHSU Knight Cancer Institute

Quick Self-Assessment

See if you qualify for this Portland location

Preparing your pre-screening questions…

Expert Care in Portland

Access atrial fibrillation specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related atrial fibrillation treatment provided free

Apply for This Portland Location

Check if you qualify for this atrial fibrillation clinical trial in Portland, OR

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Portland

    Convenient for OR residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Portland site if eligible
  4. 4Begin participation

About This Atrial Fibrillation Study in Portland

This phase II trial studies how well amiodarone works in the prevention of atrial fibrillation (AF) after a minimally invasive esophagectomy (MIE) in patients with esophageal cancer. Atrial fibrillation (AF) is an irregular heart rhythm, usually associated with a rapid rate, that is caused by abnormal electrical activity within the atria. AF is the most common complication after MIE for esophageal cancer. There has never been a study of AF after MIE that has used unbiased assignment of patients to receive preventative amiodarone or not. Further, there is no standard recommendation or guideline for preventative medications, such as amiodarone, to decrease the risk of AF in patients having MIE performed for cancer. In fact, most medical centers in the United States and around the world do not give preventative amiodarone after esophagectomy. Giving amiodarone after MIE surgery may be able to reduce the risk of AF for patients with esophageal cancer.

Sponsor: OHSU Knight Cancer Institute

Who Can Participate

Inclusion Criteria

All patients undergoing MIE will be evaluated for potential enrollment
Indication of cancer, esophageal dysplasia or esophageal dysmotilities
Age \> 18 years
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

History of chronic or paroxysmal AF, or atrial flutter
Previous severe adverse reaction or contraindication to amiodarone (e.g., pulmonary toxicity/fibrosis, hepatotoxicity, thyroid dysfunction)
Current preoperative use of amiodarone, as baseline home medication
Development of AF intraoperatively
Negative pregnancy tests are required for participants of childbearing potential (PCBP) on Day of Surgery (DOS)
Breastfeeding/chest feeding
Aborted MIE operation
QTcF (Fridericia formula) \> 500 for heart rate (HR) 60-100 within 30 days
For patients with a heart rate (HR) of between 50-59 on their pre-operative screening electrocardiography (EKG), we will first review evidence of chronotropic cardiac response to exercise before inclusion in the study. If a patient's HR increases to ≥ 100 with exercise, the patient is eligible for inclusion of study. Exercise testing options may include a stair climb, a brisk walk, or supine leg-lifts prior to surgery. If exercise is not an option, we can review results of formal stress testing chronotropic response (ie. HR ≥ 100). HR monitoring can be collected by either pulse oximeter or EKG

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Portland?

Yes, this clinical trial (NCT06067438) has an active research site in Portland, OR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Atrial Fibrillation Treatment Options in Portland, OR

If you're searching for atrial fibrillation treatment options in Portland, OR, this clinical trial (NCT06067438) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Portland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced atrial fibrillation specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all atrial fibrillation clinical trials near you to find additional studies recruiting in your area.

More Atrial Fibrillation Trials in Portland, OR

See all atrial fibrillation clinical trials recruiting in Portland — not just this study.

Browse Atrial Fibrillation Trials in Portland

Browse More Trials by Condition

Ready to Join in Portland?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Portland, OR